Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to ...

In the latest close session, Novavax (NVAX) was down 1.97% at $9.71. This change lagged the S&P 500's 0.55% gain on the day.

The cancer diagnostics company is taking a different path to the public markets after a planned merger collapsed last year.

The unprecedented changes have led to diminished vaccine usage, and created a drag that will likely dent revenues.

Sweeping U.S. policy changes under Health Secretary Robert F. Kennedy Jr. are having a ‌chilling effect ​on vaccine makers as ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary ...

Health Canada is planning to speed up reviews of some drugs by piggybacking on the decisions of foreign regulators, including ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.